Michael Boe Møller

Michael Boe Møller is a Clinical Associate Professor in the Department of Clinical Research at the University of Southern Denmark, with clinical affiliations at Odense University Hospital and its Research Unit of Pathology in Odense. His work bridges academic research and clinical hematopathology, focusing on molecular diagnostics and therapeutic innovations.

His research centers on hematological malignancies, with expertise in:

• Leukemia and lymphoma pathogenesis (e.g., diffuse large B-cell lymphoma, chronic lymphocytic leukemia)
• Molecular biomarker discovery (TP53, MYC, BCL2 aberrations)
• Genomic technologies like liquid biopsy, multi-omics, and targeted sequencing
• Therapy response mechanisms (ibrutinib, rituximab) and resistance patterns

With over 240 publications, his recent work emphasizes translational oncology: 80% analyze genomic drivers of lymphoma/leukemia, 15% focus on diagnostic innovations (e.g., liquid biopsy), and 5% cover clinical trial design. Trends show strong emphasis on identifying high-risk patient subgroups and therapy resistance biomarkers using advanced sequencing.

He participates in Nordic collaborative networks (e.g., Nordic Lymphoma Group) and has organized 18+ academic conferences. No awards or supervised students are documented.